Skip to content
6CCVD Research

The First Electroanalytical Study Of Umifenovir (Arbidol) Used As A Potential Antiviral Drug For The Treatment of SARS-CoV-2 - A Voltammetric Quantification On The Boron-Doped Diamond Electrode By Using Anionic Surfactant Media

At a Glance

Section titled “At a Glance”
MetadataDetails
Publication Date2023-01-01
JournalJournal of The Electrochemical Society
AuthorsHande Ä°zem Özok, Musa Kıran, Oruç Yunusoğlu, Yavuz Yardım
InstitutionsBolu Abant Ä°zzet Baysal University, Van YĂŒzĂŒncĂŒ Yıl Üniversitesi
Citations7

Abstract

Section titled “Abstract”

In this work, an electroanalytical procedure for sensing umifenovir (arbidol) by square wave adsorptive stripping voltammetry (SW-AdSV) was developed utilizing an anodically pretreated boron-doped diamond electrode. Measurements of umifenovir using cyclic voltammetry with phosphate buffer solution (PBS, 0.1 M, pH 2.5) revealed irreversible behaviour, adsorption-controlled as well as an ill-defined (+1.13 V, P A1 ) and a well-defined (+1.47 V, P A2 ) two oxidation peaks. Umifenovir oxidations depend critically on supporting electrolytes and pH. The second oxidation peak (P A2 ) current of the umifenovir was enhanced by adding sodium dodecyl sulfate (SDS, anionic surfactant) in the chosen supporting electrolyte. Umifenovir was quantified using its second oxidation peak (P A2 ) at about +1.39 V. Using the optimized condition, the oxidation peak current of P A2 showed a linear relationship for umifenovir determination in the concentration range from 0.005 to 1.0 ÎŒ g ml −1 (9.73 × 10 −9 −1.95 × 10 −6 M), with a detection limit of 0.0014 ÎŒ g ml −1 (2.72 × 10 −9 M) in PBS (PH 2.5) with SDS. Finally, the developed approach was successfully utilized to determine umifenovir in the pharmaceutical formulation and urine samples. To the best of our knowledge, this is the first electroanalytical approach for voltammetric sensing of umifenovir.

Tech Support

Section titled “Tech Support”

Original Source

Section titled “Original Source”

References

Section titled “References”
  1. 2021 - One year update on the COVID-19 pandemic: Where are we now?’ [Crossref]
  2. 2014 - Arbidol as a broad-spectrum antiviral: An update [Crossref]
  3. 2022 - Phase III, randomized, double-blind, placebo controlled trial of efficacy, safety and tolerability of antiviral drug umifenovir vs standard care of therapy in non-severe COVID-19 patients [Crossref]
  4. 2021 - First electrochemical evaluation of favipiravir used as an antiviral option in the treatment of COVID-19: A study of its enhanced voltammetric determination in cationic surfactant media using a boron-doped diamond electrode [Crossref]
  5. 2022 - COVID-19: vaccines, efficacy and effects on variants [Crossref]
  6. 2020 - Protective effect of arbidol against pulmonary fibrosis and sepsis in mice
  7. 2020 - The anti-influenza virus drug, arbidol is an efficient inhibitor of SARS-CoV-2 in vitro [Crossref]
  8. 2021 - Efficacy and safety of arbidol (umifenovir) in patients with COVID-19: a systematic review and meta-analysis [Crossref]
  9. 2021 - Emergent drug and nutrition interactions in COVID-19: a comprehensive narrative review [Crossref]

Reads Similar to This

(Invited) Defect and Impurity Characterization in Wide Bandgap Materials and Interfaces - Impact on Thermal Transport High-precision robust monitoring of charge/discharge current over a wide dynamic range for electric vehicle batteries using diamond quantum sensors Special Issue on “Nanocarbon Electrochemistry and Electroanalysis”